NASDAQ:QTRX

Quanterix Stock Forecast, Price & News

$50.27
+2.56 (+5.37 %)
(As of 09/17/2021 04:00 PM ET)
Add
Compare
Today's Range
$47.73
$50.95
50-Day Range
$45.91
$59.67
52-Week Range
$31.24
$92.57
Volume432,871 shs
Average Volume263,377 shs
Market Capitalization$1.84 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.52
30 days | 90 days | 365 days | Advanced Chart
Receive QTRX News and Ratings via Email

Sign-up to receive the latest news and ratings for Quanterix and its competitors with MarketBeat's FREE daily newsletter.


Quanterix logo

About Quanterix

Quanterix Corp. engages in the development of ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics. Its products and services include Simoa Assay Kits, HD-X analyzer, SR-X Biomarker Detection System, SP-X Imaging and Analysis System, 2470 Arrayer, Simoa Accelerator Laboratory, Uman NF-Light, and Homebrew -Custom Assay Development. The company was founded by Nicholas J. Naclerio and David R. Walt in April 2007 and is headquartered in Billerica, MA.

Headlines

Does Quanterix (NASDAQ:QTRX) Have A Healthy Balance Sheet?
Does Quanterix (NASDAQ:QTRX) Have A Healthy Balance Sheet?
September 17, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

2.25 out of 5 stars

Medical Sector

297th out of 1,351 stocks

Analytical Instruments Industry

7th out of 30 stocks

Analyst Opinion: 3.2Community Rank: 4.1Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Quanterix (NASDAQ:QTRX) Frequently Asked Questions

Is Quanterix a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Quanterix in the last twelve months. There are currently 1 sell rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Quanterix stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in QTRX, but not buy additional shares or sell existing shares.
View analyst ratings for Quanterix
or view top-rated stocks.

What stocks does MarketBeat like better than Quanterix?

Wall Street analysts have given Quanterix a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Quanterix wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Quanterix's next earnings date?

Quanterix is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Quanterix
.

How were Quanterix's earnings last quarter?

Quanterix Co. (NASDAQ:QTRX) posted its quarterly earnings results on Thursday, August, 5th. The company reported ($0.33) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.32) by $0.01. The business had revenue of $25.37 million for the quarter, compared to analyst estimates of $23.59 million. Quanterix had a negative net margin of 26.90% and a negative trailing twelve-month return on equity of 8.76%.
View Quanterix's earnings history
.

How has Quanterix's stock price been impacted by COVID-19 (Coronavirus)?

Quanterix's stock was trading at $18.51 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, QTRX shares have increased by 171.6% and is now trading at $50.27.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for QTRX?

3 brokerages have issued 12-month target prices for Quanterix's shares. Their forecasts range from $53.00 to $75.00. On average, they expect Quanterix's stock price to reach $66.00 in the next twelve months. This suggests a possible upside of 31.3% from the stock's current price.
View analysts' price targets for Quanterix
or view top-rated stocks among Wall Street analysts.

Who are Quanterix's key executives?

Quanterix's management team includes the following people:
  • E. Kevin Hrusovsky, Chairman, President & Chief Executive Officer
  • William Geist, Chief Operating Officer
  • Michael A. Doyle, Chief Financial Officer & Treasurer
  • David C. Duffy, Chief Technology Officer & Vice President-Research (LinkedIn Profile)
  • Brian P. Keane, Vice President & Senior Legal Counsel

What is Kevin Hrusovsky's approval rating as Quanterix's CEO?

15 employees have rated Quanterix CEO Kevin Hrusovsky on Glassdoor.com. Kevin Hrusovsky has an approval rating of 70% among Quanterix's employees.

Who are some of Quanterix's key competitors?

What other stocks do shareholders of Quanterix own?

When did Quanterix IPO?

(QTRX) raised $50 million in an initial public offering on Thursday, December 7th 2017. The company issued 3,300,000 shares at $14.00-$16.00 per share. J.P. Morga and Leerink Partners acted as the underwriters for the IPO and BTIG and Evercore ISI were co-managers.

What is Quanterix's stock symbol?

Quanterix trades on the NASDAQ under the ticker symbol "QTRX."

Who are Quanterix's major shareholders?

Quanterix's stock is owned by many different institutional and retail investors. Top institutional investors include Macquarie Group Ltd. (7.73%), BlackRock Inc. (6.58%), Vanguard Group Inc. (4.39%), Price T Rowe Associates Inc. MD (3.94%), Marshall Wace LLP (3.87%) and Frontier Capital Management Co. LLC (2.65%). Company insiders that own Quanterix stock include Amol Chaubal, David C Duffy, David C Duffy, David R Walt, Dawn Mattoon, E Kevin Hrusovsky, John J Fry, John J Fry, Marijn E Dekkers, Mark T Roskey and Martin D Madaus.
View institutional ownership trends for Quanterix
.

Which institutional investors are selling Quanterix stock?

QTRX stock was sold by a variety of institutional investors in the last quarter, including Price T Rowe Associates Inc. MD, Lord Abbett & CO. LLC, Morgan Stanley, Morgan Stanley, Monashee Investment Management LLC, Bellevue Group AG, Redmile Group LLC, and Victory Capital Management Inc.. Company insiders that have sold Quanterix company stock in the last year include Amol Chaubal, David C Duffy, Dawn Mattoon, E Kevin Hrusovsky, John J Fry, Marijn E Dekkers, Mark T Roskey, and Martin D Madaus.
View insider buying and selling activity for Quanterix
or view top insider-selling stocks.

Which institutional investors are buying Quanterix stock?

QTRX stock was acquired by a variety of institutional investors in the last quarter, including Macquarie Group Ltd., Millennium Management LLC, BlackRock Inc., Marshall Wace LLP, Clearbridge Investments LLC, Skandinaviska Enskilda Banken AB publ, Frontier Capital Management Co. LLC, and Monarch Partners Asset Management LLC.
View insider buying and selling activity for Quanterix
or or view top insider-buying stocks.

How do I buy shares of Quanterix?

Shares of QTRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Quanterix's stock price today?

One share of QTRX stock can currently be purchased for approximately $50.27.

How much money does Quanterix make?

Quanterix has a market capitalization of $1.84 billion and generates $86.38 million in revenue each year. The company earns $-31,530,000.00 in net income (profit) each year or ($1.10) on an earnings per share basis.

How many employees does Quanterix have?

Quanterix employs 314 workers across the globe.

What is Quanterix's official website?

The official website for Quanterix is www.quanterix.com.

Where are Quanterix's headquarters?

Quanterix is headquartered at 900 MIDDLESEX TURNPIKE, BILLERICA MA, 01821.

How can I contact Quanterix?

Quanterix's mailing address is 900 MIDDLESEX TURNPIKE, BILLERICA MA, 01821. The company can be reached via phone at (617) 301-9400 or via email at [email protected]


This page was last updated on 9/17/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.